Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 145-154
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.145
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.145
Antiviral drugs | Resistance mutations | HBsAg correspondingchanges |
Lamivudine (LAM2) Tebivudine (LdT2) | rtL180M | No change |
rtM204V | sI195M | |
rtM204I2 | sW1961/S/L | |
Adefovir (AdV) Tenofovir (TDF) LAM2 | rtA181T2 | sW1721 |
rtA181T2 | sW172L | |
rtA181V2 | sL173F | |
rtN236T | After end of HBs open reading frame | |
Entecavir (ETV) | rtI169T | sF161H/L |
rtT184A | No change | |
rtT184C | sL175F + sL176V | |
rtT184I | No change | |
rtT184G | sL176V | |
rtT184S | sL175F | |
rtT184M | sL1761 | |
rt184L | sL175F | |
rtS202C | No change/sS193F | |
rtS202I | sV194F/S | |
rtS202G | No change/sS193L | |
rtM250I | After end of HBs open reading frame | |
rtM250V | After end of HBs open reading frame |
- Citation: Caligiuri P, Cerruti R, Icardi G, Bruzzone B. Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 2016; 22(1): 145-154
- URL: https://www.wjgnet.com/1007-9327/full/v22/i1/145.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i1.145